High-throughput proteomic characterization of plasma rich in growth factors (PRGF-Endoret)-derived fibrin clot interactome

Journal of Tissue Engineering and Regenerative Medicine

Volumn 9, Issue 11, 2015, Pages E1-E12

  Anitua, Eduardo ^a,d   Prado, Roberto ^a   Azkargorta, Mikel ^b   Rodriguez Suárez, Eva ^b   Iloro, Ibon ^b   Casado Vela, Juan ^c   Elortza, Felix ^b   Orive, Gorka ^a,d  

^a BTI Biotechnology Institute   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^d Foundation Eduardo Anitua   (Spain)

Author keywords

Fibrin clot; Plasma rich in growth factors; Platelet rich plasma; Proteomics; Scaffold; Tissue regeneration

Indexed keywords

GENE ONTOLOGY; MOLECULAR BIOLOGY; PROTEINS; SCAFFOLDS (BIOLOGY); TISSUE;

FIBRIN CLOTS; FIBRIN SCAFFOLD; HEALING PROCESS; HIGH-THROUGHPUT; INTERACTOME; PLASMA RICH IN GROWTH FACTORS; PLATELET RICH PLASMA; PROTEOMICS; WOUND HEALING; WOUND TISSUE;

TISSUE REGENERATION;

BIOMATERIAL; FIBRIN; PEPTIDE; PLASMA PROTEIN; PROTEIN; PROTEOME; SIGNAL PEPTIDE; TRYPSIN;

ARTICLE; CONTROLLED STUDY; GENE ONTOLOGY; HEMATOLOGICAL PARAMETERS; HEMATOLOGICAL PROCEDURE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEOMICS; SCANNING ELECTRON MICROSCOPY; THREE DIMENSIONAL IMAGING; THROMBOCYTE RICH PLASMA; TISSUE REGENERATION; TISSUE SCAFFOLD; TWO DIMENSIONAL GEL ELECTROPHORESIS; WOUND HEALING; BIOTECHNOLOGY; BLOOD CLOTTING; CHEMISTRY; CYTOLOGY; LEUKOCYTE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; NORMAL HUMAN; PROCEDURES; REGENERATION; REGENERATIVE MEDICINE; TANDEM MASS SPECTROMETRY; THROMBOCYTE; TISSUE ENGINEERING; TRANSMISSION ELECTRON MICROSCOPY;

BIOTECHNOLOGY; BLOOD COAGULATION; BLOOD PLATELETS; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRIN; HEALTHY VOLUNTEERS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDES; PROTEINS; PROTEOME; REGENERATION; REGENERATIVE MEDICINE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TRYPSIN; WOUND HEALING;

EID: 84946491343     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1721     Document Type: Article

References (54)

1. Adams JC, Lawler J. 2004; The thrombospondins. Int J Biochem Cell Biol 36: 961-968.
2. Aebersold R, Mann M. 2003; Mass spectrometry-based proteomics. Nature 422: 198-207.
3. Anderson NL, Anderson NG. 2002; The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteom 1: 845-867.
4. Angles-Cano E, de la Pena Diaz A, Loyau S. 2001; Inhibition of fibrinolysis by lipoprotein (a). Ann. NY Acad. Sci 936: 261-275.
5. Anitua E. 1999; Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 14: 529-535.
6. Anitua E, Alkhraisat MH, Orive G. 2012a; Perspectives and challenges in regenerative medicine using plasma rich in growth factors. J Control Release 157: 29-38.
7. Anitua E, Alonso R, Girbau C, et al. 2012b; Antibacterial effect of plasma rich in growth factors [PRGF(R)-Endoret(R)] against Staphylococcus aureus and Staphylococcus epidermidis strains. Clin Exp Dermatol 37: 652-657.
8. Anitua E, Andia I, Ardanza B, et al. 2004; Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 91: 4-15.
9. Anitua E, Sanchez M, Orive G. 2010; Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev 62: 741-752.
10. Anitua E, Sanchez M, Orive G, et al. 2007; The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 28: 4551-4560.
11. Anitua E, Sanchez M, Orive G, et al. 2008; Delivering growth factors for therapeutics. Trends Pharmacol Sci 29: 37-41.
12. Anitua E, Sanchez M, Prado R, et al. 2011a; The P makes the difference in plasma rich in growth factors (PRGF) technology. Platelets 22: 473-474; author reply, 475.
13. Anitua E, Sanchez M, Prado R, et al. 2011b; Plasma rich in growth factors: the pioneering autologous technology for tissue regeneration. J Biomed Mater Res A 97: 536.
14. Anitua E, Sanchez M, Zalduendo MM, et al. 2009; Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif 42: 162-170.
15. Ashburner M, Ball CA, Blake JA, et al. 2000; Gene Ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet 25: 25-29.
16. Bendinelli P, Matteucci E, Dogliotti G, et al. 2010; Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. J Cell Physiol 225: 757-766.
17. Blair P, Flaumenhaft R. 2009; Platelet α-granules: basic biology and clinical correlates. Blood Rev 23: 177-189.
18. Bulat N, Waeber G, Widmann C. 2009; LDLs stimulate p38 MAPKs and wound healing through SR-BI independently of Ras and PI3 kinase. J Lipid Res 50: 81-89.
19. Casado-Vela J, Rodriguez-Suarez E, Iloro I, et al. 2009; Comprehensive proteomic analysis of human endometrial fluid aspirate. J Proteome Res 8: 4622-4632.
20. Chen FM, Zhang M, Wu ZF. 2010; Toward delivery of multiple growth factors in tissue engineering. Biomaterials 31: 6279-6308.
21. Dobreva I, Waeber G, Mooser V, et al. 2003; LDLs induce fibroblast spreading independently of the LDL receptor via activation of the p38 MAPK pathway. J Lipid Res 44: 2382-2390.
22. Ebersole JL, Cappelli D. 2000; Acute-phase reactants in infections and inflammatory diseases. Periodontol 2000 2000 23: 19-49.
23. Gabay C, Kushner I. 1999; Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454.
24. Gelse K, Klinger P, Koch M, et al. 2011; Thrombospondin-1 prevents excessive ossification in cartilage repair tissue induced by osteogenic protein-1. Tissue Eng Part A 17: 2101-2112.
25. Greiling D, Clark RA. 1997; Fibronectin provides a conduit for fibroblast transmigration from collagenous stroma into fibrin clot provisional matrix. J Cell Sci 110(7): 861-870.
26. Han YP, Yan C, Garner WL. 2008; Proteolytic activation of matrix metalloproteinase-9 in skin wound healing is inhibited by α1-antichymotrypsin. J Invest Dermatol 128: 2334-2342.
27. Hasumi K, Yamamichi S, Harada T. 2010; Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems. FEBS J 277: 3675-3687.
28. Hoffmann DC, Textoris C, Oehme F, et al. 2011; Pivotal role for α1-antichymotrypsin in skin repair. J Biol Chem 286: 28889-28901.
29. Kalsheker N. 1989; α1-Antitrypsin: structure, function and molecular biology of the gene. Biosci Rep 9: 129-138.
30. Law RH, Zhang Q, McGowan S, et al. 2006; An overview of the serpin superfamily. Genome Biol 7: 216.
31. Lin F, Ren XD, Pan Z, et al. 2011; Fibronectin growth factor-binding domains are required for fibroblast survival. J Invest Dermatol 131: 84-98.
32. Macri L, Silverstein D, Clark RA. 2007; Growth factor binding to the pericellular matrix and its importance in tissue engineering. Adv Drug Deliv Rev 59: 1366-1381.
33. Mazzucco L, Borzini P, Gope R. 2010; Platelet-derived factors involved in tissue repair - from signal to function. Transfus Med Rev 24: 218-234.
34. McNicol A, Israels SJ. 1999; Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 95: 1-18.
35. Mosher DF, Misenheimer TM, Stenflo J, et al. 1992; Modulation of fibrinolysis by thrombospondin. Ann. NY Acad. Sci 667: 64-69.
36. Mozzati M, Martinasso G, Pol R, et al. 2010; The impact of plasma rich in growth factors on clinical and biological factors involved in healing processes after third molar extraction. J Biomed Mater Res A 95: 741-746.
37. Nurden AT, Nurden P, Sanchez M, et al. 2008; Platelets and wound healing. Front Biosci 13: 3532-3548.
38. Ogawa T, Nishimura I. 2006; Genes differentially expressed in titanium implant healing. J Dent Res 85: 566-570.
39. Pankov R, Yamada KM. 2002; Fibronectin at a glance. J Cell Sci 115: 3861-3863.
40. Podor TJ, Campbell S, Chindemi P, et al. 2002; Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and γA/γ' fibrinogen. J Biol Chem 277: 7520-7528.
41. Podor TJ, Peterson CB, Lawrence DA, et al. 2000; Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem 275: 19788-19794.
42. Preissner KT, Reuning U. 2011; Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 37: 408-424.
43. Reiss MJ, Han YP, Garner WL. 2009; α1-Antichymotrypsin activity correlates with and may modulate matrix metalloproteinase-9 in human acute wounds. Wound Repair Regen 17: 418-426.
44. Steen H, Mann M. 2004; The ABCs (and XYZs) of peptide sequencing. Nat Rev Mol Cell Biol 5: 699-711.
45. Tirumalai RS, Chan KC, Prieto DA, et al. 2003; Characterization of the low molecular weight human serum proteome. Mol. Cell Proteom 2: 1096-1103.
46. van Buul GM, Koevoet WL, Kops N, et al. 2011; Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 39: 2362-2370.
47. von Zychlinski A, Kleffmann T, Williams MJ, et al. 2011; Proteomics of lipoprotein (a) identifies a protein complement associated with response to wounding. J. Proteom 74: 2881-2891.
48. Wang-Saegusa A, Cugat R, Ares O, et al. 2011; Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life. Arch Orthop Trauma Surg 131: 311-317.
49. Weisel JW. 2005; Fibrinogen and fibrin. Adv Protein Chem 70: 247-299.
50. Werner S, Grose R. 2003; Regulation of wound healing by growth factors and cytokines. Physiol Rev 83: 835-870.
51. Wolberg AS. 2010; Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia 16(suppl 3): 7-12.
52. Woodley DT, Fan J, Cheng CF, et al. 2009; Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90α autocrine signaling to promote keratinocyte migration. J Cell Sci 122: 1495-1498.
53. Yano Y, Seishima M, Tokoro Y, et al. 1998; Stimulatory effects of lipoprotein (a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2. Biochim Biophys Acta 1393: 26-34.
54. Yano Y, Shimokawa K, Okada Y, et al. 1997; Immunolocalization of lipoprotein (a) in wounded tissues. J Histochem Cytochem 45: 559-568.